Overview

Safety and Efficacy of Lacosamide as Additional Therapy in Patients Suffering From Epileptic Tonic-Clonic Seizures

Status:
Active, not recruiting

Trial end date:
2024-02-01

Target enrollment:

Participant gender:

Summary

Assessment of long-term safety and efficacy of oral lacosamide (LCM) as an adjunctive therapy for uncontrolled primary generalized tonic-clonic seizures (PGTCS) in subjects >= 4 years of age with idiopathic generalized epilepsy (IGE). This study will enroll subjects from the LCM SP0982 [NCT02408523] study.

Phase:

Phase 3

Details

Lead Sponsor:

UCB BIOSCIENCES, Inc.

Treatments:

Lacosamide
Pharmaceutical Solutions